Mesenchymal stem cells (MSCs) may offer therapeutic benefit in the setting of sepsis and endotoxemia.
INTRODUCTION
Mesenchymal stem cells (MSCs) represent a promising therapeutic modality for a variety of diseases. In sepsis, MSCs use paracrine signaling mechanisms to counteract the physiologic derangements and multi-organ dysfunction created by an overwhelming systemic inflammatory response to invading pathogens (42, 43) . They have been shown to prevent apoptosis, decrease systemic and local pro-inflammatory cytokines, augment anti-inflammatory mediators, preserve organ function, and upregulate bacterial killing in response to LPS and other inflammatory stimuli (14, 16, 24).
They have been successfully employed in murine endotoxemia and cecal ligation and puncture models to decrease both the clinical symptoms and histopathologic severity of organ damage, increase survival times, and modulate the immune response (26, 43). Similar improvement can be noted in acute lung injury models utilizing MSCs to combat the effects of overwhelming infection (16, 20) .
Of interest, MSCs appear to exhibit sex-specific characteristics which may impact their ability to protect injured tissue. Our group has noted sex differences in MSC function after exposure to LPS, hypoxia, and hydrogen peroxide with increases in protective factors and decreases in pro-inflammatory factors noted in female-derived murine MSCs over that of male-derived MSCs (8). In addition, we have demonstrated that treatment with female MSCs improves myocardial functional recovery to a greater extent than male MSCs in a cardiac I/R injury model (6). This disparity in male and female MSC protective capability may be due in part to differing levels of receptors or intracellular signaling enzymes that are activated in response to exogenous stressors as well as the relative importance of these pathways in producing outcomes. In fact, studies involving tumor necrosis factor receptor 1 (TNFR1) ablation in MSCs exposed to LPS show an inherent resistance of female MSCs to the increased proinflammatory cytokine and decreased growth factor production of male MSCs (7).
The concept of a sex bias in disease has been previously recognized. Sex hormones have been shown to influence outcomes after trauma-hemorrhage, I/R injury, and sepsis (5, 19, 40) . Increasing evidence suggests that sex steroids, specifically estrogen, may help normalize organ function and ameliorate the inflammatory response through paracrine actions on immune cells and host tissue (19, 37, 44) . Indeed, studies involving males and ovariectomized females given exogenous estrogen support this hypothesis of a sex partiality in ischemia and sepsis (5, 40) . Additional research has identified decreased activation of the pro-inflammatory p38 MAPK pathway in the female sex after both ischemic and endotoxemic insults and increased anti-apoptotic mechanisms (15, 25, 38, 47) .
However, it is unknown whether sex-specific MSCs can also ameliorate tissue injury in sepsis and provide cardioprotection. We hypothesized that treatment with female MSCs would improve myocardial functional recovery, decrease systemic and myocardial inflammation and alter the myocardial profile to a more anti-apoptotic state to a greater extent than treatment with male MSCs in a rat endotoxemia model. Furthermore, we hypothesized that this decrease in myocardial inflammation would be associated with MSC paracrine-mediated downregulation of the p38 MAPK pathway.
METHODS

Animals.
Adult male Sprague-Dawley rats weighing 250-300g (Harlan, Indianapolis, IN) were fed a standard diet and placed in isolation for acclimation purposes for one week prior to experimentation.
through the left atrium to the left ventricle to measure EDP. The heart was perfused in the Langendorff mode and paced at 350 bpm. Pulmonary artery effluent was collected to measure coronary flow. Data was recorded using MacLab 8 preamplifier/digitizer software (AD Instruments Inc., Milford, MA).
Maximal positive and negative values of the first derivative of pressure (+dP/dt and -dP/dt, respectively) were calculated using PowerLab software (AD Instruments Inc., Colorado Springs, CO). At end-perfusion, hearts were sectioned, snap-frozen in liquid nitrogen, and stored at -80°C for later analysis.
ELISA. Homogenized heart tissue and serum samples taken from the right ventricle during rat sacrifice were centrifuged for 10 min at 12,000 rpm at 4°C and supernatants collected. Levels of IL-1β, IL-6, IL-10, and TNF-α production were measured by enzyme-linked immunosorbent assays (ELISA) using commercially available ELISA kits (R&D Systems, Minneapolis, MN). All tests on samples and standards were performed in duplicate per the manufacturer's instructions. Protein concentrations were measured using the Bradford protocol via biophotometer and used to standardize ELISA values. Results are reported as pg/mg protein.
Western Blot. The heart was homogenized and lysed in a cold radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase inhibitors (Sigma). The protein extracts (10 μg/lane) were then electrophoresed on a 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA), transferred to a nitrocellulose membrane, and blocked with 5% dry milk solution for 1 h. The membrane was then incubated with the primary antibodies p38 MAPK, phospho-p38 MAPK (Thr180/Tyr182), Bcl-xL, Bax (Cell Signaling Technology, Beverly, MA), or GAPDH (Biodesign International, Saco, ME) overnight at 4°C. Each incubation was followed secondary horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse 
RESULTS
Female MSCs offer greater preservation of myocardial function during endotoxemia. As expected, endotoxemic injury resulted in markedly depressed cardiac function in all groups (Fig 1) . Coronary flow rates mimic myocardial function. LPS injection depressed coronary flow rates in all treated groups with greater depression seen at higher EDPs of 30 and 40 mmHg (Fig 2) . The vehicle group experienced the greatest depression in flow rates over all EDPs measured from 8.25-9.38 ml/min ± 0.5 ml/min compared to 11.75-14.0 ml/min ± 0.8 ml/min in the male MSC-treated group and 14.0-15.5 ml/min ± 0.9 ml/min in the female MSC-treated group (p<0.05). A significant difference was seen between male and female MSC-treated groups at EDPs of 30 and 40 mmHg only (p<0.05). Coronary flow was preserved in the control group in comparison to the treated groups and ranged from 16.3-18.6 ml/min ± 0.9 ml/min over all EDPs measured. In general, as EDPs were sequentially increased over physiologic levels of 10 mmHg, coronary flow became increasingly impaired within groups with the exception of the female MSC-treated group.
MSC injection of either gender is associated with decreased pro-inflammatory cytokine
production and increased anti-inflammatory cytokine production. Both systemic and myocardial production of pro-inflammatory IL-1β, IL-6, and TNF-α was reduced to an equal extent in endotoxemic rats treated with either male or female MSCs compared to vehicle (Figs 3A; 3B; 3C; Figs 4A; 4B; 4C).
Control animals consistently expressed the lowest levels of all measured systemic and myocardial cytokines. Following female MSC injection, systemic and myocardial IL-1β levels were 370.9 ± 136 pg/mL and 169.8 ± 17 pg/mg protein, respectively, compared to 304.5 ± 61 pg/mL and 203.5 ± 12 pg/mg protein following male MSC injection and 844.9 ± 186 pg/mL and 366.5 ± 49 pg/mg protein in vehicles (p<0.05). Similar results were observed for systemic and myocardial IL-6 and TNF-α. MSC treatment reduced pro-inflammatory serum cytokine levels to levels comparable with control although a significant difference was observed between MSC treatment and control for myocardial IL-6 and TNF-α (p<0.05). In addition, serum IL-10 levels were substantially elevated in MSC-treated rats in comparison to both control (p<0.05) and vehicle (p<0.05) although myocardial IL-10 levels were similar between MSC treatment and vehicle.
MSC injection of either gender is associated with comparable inhibition of myocardial p38 MAPK
pathway. Myocardial p38 activation decreased in hearts treated with male or female MSCs compared to treated vehicles (Figs 5A; 5B; 5C). Phosphorylated p38 (p-p38) levels dropped by 60% in female MSCtreated animals (p<0.05) and 68% in male MSC-treated animal (p<0.05) versus vehicle and corresponded to a 59% and 65% decrease in p-p38/total p38 levels, respectively (p<0.05). There was no significant difference seen between MSC treatment or control. These findings suggest that sex-mediated MSC differences are not mediated by the p38 MAPK pathway in response to sepsis.
Female MSC injection is associated with greater myocardial anti-apoptotic profile.
Myocardial bcl-xL levels were significantly increased in rats treated with MSCs of either gender compared to vehicle and were comparable to control levels (Figs 6A; 6B). The bcl-xL/bax ratio was also increased in rats treated with MSCs of either gender compared to vehicle although female MSC-treated rats also exhibited a significantly higher ratio in comparison to male MSC-treated rats (Fig 6C; p<0 .05). These findings suggest that sex-mediated MSC differences may in part be due to alteration of the myocardial apoptotic profile during sepsis.
DISCUSSION
The inherent advantage associated with the female sex regarding the cardiovascular response in sepsis is well documented and is recognized as a major factor in survival outcomes. Our results suggest that this same sex bias may increase the protective properties of MSCs against cardiac dysfunction in a rodent model of endotoxemia. In our study, while administration of female MSCs attenuated myocardial and systemic inflammation to a similar extent as administration of male MSCs, it improved myocardial functional parameters and beneficially altered the myocardial apoptotic profile beyond that seen with administration of male MSCs.
The myocardial depression observed in sepsis is thought to be due to the endotoxin-mediated release of inflammatory mediators that alters the intracellular milieu of cardiac myocytes with resultant cardiovascular compromise. Foremost among these inflammatory cytokines are TNF-α, IL-1β, and IL-6 which directly impact intracellular signaling cascades, mitochondrial function, and levels of oxidative stress to increase cardiac work, decrease contractility, and hasten myocyte injury and death (34, 45) .
Persistent myocardial dysfunction results in hemodynamic collapse and subsequent death.
The rodent endotoxemia model used in this study reliably mimics the cardiac depression and system-wide inflammatory response observed in human sepsis. While the cecal ligation and puncture model is more clinically relevant, the endotoxemia model allows for a more rapid rise in levels of inflammatory cytokines and in deterioration of cardiac function (33) . As our aim was to determine whether the animals studied here responded favorably to either female or male MSC administration, this model provided a quicker, more efficient way to ascertain these changes. Indeed, all treatment groups experienced decreases in myocardial functional parameters across the board and elevated myocardial and serum levels of TNF-α, IL-1β, and IL-6. These changes were significantly blunted in both male and female MSC-treated rats compared to vehicles to a similar degree.
Prior studies have attempted to elucidate the properties by which MSCs appear to confer benefit in the septic host. Gene expression analysis in a rodent CLP model showed an association between MSC treatment, down-regulation of systemic inflammatory genes and up-regulation of genes involving phagocytosis, antigen presentation, and bacterial killing in innate immune cells (24). Other groups have used co-culture experiments to provide evidence that MSCs mediate the majority of their effects through paracrine mechanisms (16, 43) . Our lab has previously observed that MSC administration provides cardioprotection in an endotoxemia model and that this protection may in part by mediated by MSC-induced up-regulation of IL-10 expression by peritoneal macrophages (41) . The mechanism behind this hypothesis states that IL-10, an endogenous anti-inflammatory mediator, reduces the production of pro-inflammatory cytokines and limits the propagation of the inflammatory cascade by inhibiting the activation of peritoneal macrophages (14, 26). Less systemic inflammation results in less direct inflammation-induced insult to the endotoxemic heart. Indeed, our examination of serum IL-10 levels proved to be in concordance with this theory. In contrast, while levels of myocardial IL-10 were significantly elevated after both male and female MSC treatment in comparison to control, they did not differ from vehicle levels, which suggests that the myocardial injury sustained in our experiment was still in the earliest phases and that myocardial IL-10 levels were still in the process of rising. We anticipate that had the timing of the experiment been extended beyond 6 hours, we would have seen an additional rise in myocardial IL-10 levels in rats treated with MSCs of either gender.
While MSC administration in general correlated with considerable improvements in endotoxemic myocardial function versus vehicle, MSCs from female donors were associated with an additional 20.1% increase in LVDP, 25.4% increase in +dP/dt, and 25.5% decrease in -dP/dt on average over MSCs from male donors. In addition, the rates of coronary flow decreased in parallel to myocardial LVDP among all groups. Coronary flow rates were highest in the control group and lowest in the vehicle group with evidence of equal preservation of flow among the MSC treatment groups, although they did not reach the level of controls. This greater preservation of myocardial function is likely not attributable to levels of myocardial or systemic pro-inflammatory cytokines since MSC injection of either gender was associated with equivalent reductions in these parameters. Likewise, activation of the myocardial p38 MAPK pathway, which is required for pro-inflammatory cytokine production and contributes to the contractile dysfunction seen in the endotoxemia, was comparable among MSC treatment groups and substantially lower than vehicle levels (28, 39). Instead, this preferential improvement in myocardial function may be due to a more significant alteration in the myocardial apoptotic profile observed after treatment with female MSCs.
Prior studies have shown that females experience a distinct advantage in trauma-hemorrhage, I/R injury, and sepsis (5, 19, 40). On the level of the stem cell, the female sex has enhanced stem cell function and reparative capabilities. Female MSCs exposed to a variety of stressful conditions have greater protective factor and decreased inflammatory mediator production as well as increased resistance to apoptosis when compared to male MSCs (7, 8). In vivo animal models have pointed to improved organ function as well as decreased tissue damage in the form of apoptosis, necrosis, and inflammation (6, 46). Female MSCs appear to mediate some of these effects through pathways that differ from male MSCs. Wang et al. demonstrated a reliance of male MSCs, but not female MSCs, on TNFR1 receptor expression for VEGF, TNF-α, and IL-6 production (7). Female MSCs also exhibit decreased apoptosis and increased levels of the protective factor VEGF in response to LPS and hypoxia when compared to male MSCs (8). These findings suggest that female MSCs may inherently have a greater resistance to injury which allows for their enhanced effects on host protection. Estrogen has been proposed as a possible mechanism to explain the protective advantage females experience following several forms of acute injury and may also come into play at the stem cell level. Indeed, the addition of estradiol has been shown to upregulate both male and female MSC function while testosterone may negatively affect both MSC and organ function (4, 9, 17, 31, 32). Furthermore, estrogen-preconditioned male MSCs have been shown to improve cardiac recovery following myocardial ischemia (12) . However, the ability of female MSCs to provide enhanced protection in the absence of estrogen stimulation indicates that multiple factors are involved in activating the intracellular pathways involved in female stem cell activation.
One of these factors may ultimately involve alteration of the apoptotic profile in endotoxemic cardiomyocytes. Administration of LPS in our study significantly depressed the levels of anti-apoptotic bcl-xL in the myocardium as well as decreasing the bcl-xL/bax ratio, thereby suggesting a shift to increased myocardial apoptosis through a combination of decreased expression of anti-apoptotic proteins (such as bcl-xL) and increased expression of pro-apoptotic proteins (such as bax). This shift toward a pro-apoptotic state is a commonly observed pathophysiologic mechanism leading to sepsisinduced myocardial dysfunction (10, 36) . In contrast, administration of MSCs from male or female hosts preserved the level of bcl-xL in the myocardium while increasing the overall ratio of bcl-xL to bax. In addition, female MSC treatment was found to have a significantly increased bcl-xL/bax ratio over that of male MSC treatment and may be one reason as to why superior preservation of cardiac function was observed with female MSC treatment in our study. Indeed, the enhanced anti-apoptotic properties associated with the female gender is but one reason why females have better outcomes following sepsis (30).
We would be remiss if we did not comment on the limitations of this study. Our study was designed to determine whether stem cell gender had an effect on the heart in the setting of endotoxemia. However, we specifically chose to work solely with male rats in order to remove the influence of the female environment on final outcomes so we do not know the effects of male MSCs on female rats. Our reasoning for this omission was to remove the influence of the female environment on cardiac function. Specifically, the so-called female advantage following sepsis has been partially attributed to the protective effects of estrogen. Removing this variable from the research environment allowed us to observe that female MSCs provided superior protection following endotoxemia irrespective of extraneous hormonal influences and suggests that there are inherent qualities in the female MSC that render it more effective in providing cardioprotection following endotoxemia over male MSCs.
While female MSCs have also been shown to have superior benefit over male MSCs in I/R injury, their potential in septic disease may arguably surpass their potential in I/R injury (6). Data examining several outcome parameters following coronary revascularization and coronary artery bypass grafting has actually shown females to have worse outcomes compared to males (18, 23). In contrast, males are more likely to experience detrimental outcomes following sepsis, including multi-organ dysfunction syndrome, more significant cytokine alterations and higher mortality rates (13, 35) . Estrogen plays an important role in maintaining the immune response following septic injury, but giving sick patients exogenous hormones entails its own risks. We've shown that female MSCs offer enhanced protection irrespective of estrogen stimulation, which suggests that the female advantage extends to the level of the stem cell. The potential of this treatment lies in the idea that MSCs can function dynamically at multiple levels and may be able to adapt to changes in the environment. Therefore, the potential of female MSCs to regulate inflammation across the breadth of sepsis may provide greater overall protection than in I/R injury in which an ischemic hit at a specific timepoint is minimized to preserve myocardial function.
A second limitation involves our use of murine MSCs in a rat model which has the potential for cross-reactivity. However, a number of studies has shown that the use of allogeneic and xenogenic MSCs does not appear to activate the immune system and can positively modulate local immune responses (2, 11, 21) . In addition, both murine and human MSCs have been successfully transplanted long-term in rat hearts without evidence of immune rejection or immunosuppression (3, 21) . Our lab has performed extensive research using murine MSCs in the rat model and has consistently observed the beneficial effects attributable to MSCs following both I/R and endotoxemic injuries (6, 12, 41). While rat MSCs could have been used to the same effect in this model, our main interest lies in the potential of targeted genetic manipulations of MSCs to increase their overall effectiveness in disease states. The main endpoint of this study was to conduct a baseline comparison of the inherent capabilities of male and female MSCs in an endotoxemic environment to determine whether a difference existed in their protective abilities, as our lab has previously shown for I/R injury. As a difference does indeed exist, we can now perform additional experiments incorporating genetically altered MSCs to good effect while comparing results with the known baseline function of female and male MSCs in endotoxemia.
Lastly, we paced the hearts as opposed to allowing them to beat spontaneously as would naturally occur. An inherent limitation of the ex vivo Langendorff protocol is its inability to mimic the physiologic environment of an animal model. However, it does provide critical information on heart function through the control of specific independent variables. We chose to control EDP along a range of physiologic and supraphysiologic pressures in order to observe the compensatory abilities of the rat heart at pressures that could potentially be seen during sepsis. For similar reasons, we chose to control heart rates in order to focus on contractile function since this is usually the deciding factor in maintaining systemic pressures. Had we not controlled for heart rates, we would not have been able to tease out whether a low LVDP was due to myocardial damage impeding contractile ability or to a too rapid heart rate that did not allow for sufficient filling times. Additionally, from a clinical perspective, septic patients are usually placed immediately on rate control medications to good effect while their blood pressure tends to remain labile over a period of time. Therefore, controlling heart rates in our experiments allowed us to focus on the critical variables of heart function that determine whether heart failure will occur and which can affect survival rates in sepsis.
Taken together, this data suggests that mesenchymal stem cells are effective in limiting cardiac dysfunction in the setting of endotoxemia. Female MSCs provide greater protection over that seen with male MSC administration in part through increased normalization of the myocardial Bcl-xL/Bax ratio in order to facilitate greater preservation of cardiomyocyte function. Sex differences in the pro-and antiinflammatory response to septic injury do not appear to extend to the stem cell since myocardial and systemic cytokine production were equivalent following MSC treatment of either gender. However, the greater shift toward an anti-apoptotic profile in female MSC-treated rats suggests that the benefits of female MSC treatment involve additional mechanisms beyond that of the well-subscribed sex hormone theory. Manipulating the beneficial properties of female MSCs may therefore provide another avenue through which to expand the potential role of stem cell use in sepsis.
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